CCR1 and neoplasm: The combination of a CCR1 antagonist, CCX9588, with an anti-PDL1 antibody has proven to be a promising therapeutic approach, as it resulted in synergistic antitumoral effects by inhibiting primary tumor growth and lung metastasis in an orthotopic breast cancer mouse model [96].